An 800mg daily dose of the integrase inhibitor raltegravir (Isentress) is a good alternative to the NNRTI efavirenz (Sustiva, also in Atripla) for people undergoing treatment for TB.
Therapy for TB works well in people with HIV, but there are interactions between some anti-HIV drugs and some of the drugs used to treat TB.
Earlier research had shown that an interaction between raltegravir and the key anti-TB drug rifampicin led to a reduction in raltegravir levels.
To overcome this interaction, researchers doubled the standard dose of raltegravir to 800mg each day.
They found that people treated with this dose were as likely as those taking HIV treatment based on efavirenz to suppress their viral load.